OptiNose Future Growth

Future criteria checks 5/6

OptiNose is forecast to grow earnings and revenue by 70% and 27.9% per annum respectively while EPS is expected to grow by 71.6% per annum.

Key information

70.0%

Earnings growth rate

71.6%

EPS growth rate

Pharmaceuticals earnings growth23.9%
Revenue growth rate27.9%
Future return on equityn/a
Analyst coverage

Low

Last updated13 Nov 2024

Recent future growth updates

Earnings Release: Here's Why Analysts Cut Their OptiNose, Inc. (NASDAQ:OPTN) Price Target To US$3.50

Nov 15
Earnings Release: Here's Why Analysts Cut Their OptiNose, Inc. (NASDAQ:OPTN) Price Target To US$3.50

Recent updates

OptiNose, Inc. (NASDAQ:OPTN) Might Not Be As Mispriced As It Looks After Plunging 31%

Nov 26
OptiNose, Inc. (NASDAQ:OPTN) Might Not Be As Mispriced As It Looks After Plunging 31%

Earnings Release: Here's Why Analysts Cut Their OptiNose, Inc. (NASDAQ:OPTN) Price Target To US$3.50

Nov 15
Earnings Release: Here's Why Analysts Cut Their OptiNose, Inc. (NASDAQ:OPTN) Price Target To US$3.50

Slammed 34% OptiNose, Inc. (NASDAQ:OPTN) Screens Well Here But There Might Be A Catch

Sep 27
Slammed 34% OptiNose, Inc. (NASDAQ:OPTN) Screens Well Here But There Might Be A Catch

Market Cool On OptiNose, Inc.'s (NASDAQ:OPTN) Revenues Pushing Shares 30% Lower

Aug 11
Market Cool On OptiNose, Inc.'s (NASDAQ:OPTN) Revenues Pushing Shares 30% Lower

Not Many Are Piling Into OptiNose, Inc. (NASDAQ:OPTN) Stock Yet As It Plummets 42%

Apr 27
Not Many Are Piling Into OptiNose, Inc. (NASDAQ:OPTN) Stock Yet As It Plummets 42%

There's Reason For Concern Over OptiNose, Inc.'s (NASDAQ:OPTN) Massive 32% Price Jump

Mar 01
There's Reason For Concern Over OptiNose, Inc.'s (NASDAQ:OPTN) Massive 32% Price Jump

Revenues Working Against OptiNose, Inc.'s (NASDAQ:OPTN) Share Price

Dec 28
Revenues Working Against OptiNose, Inc.'s (NASDAQ:OPTN) Share Price

OptiNose, Inc. (NASDAQ:OPTN) Might Not Be As Mispriced As It Looks After Plunging 29%

May 23
OptiNose, Inc. (NASDAQ:OPTN) Might Not Be As Mispriced As It Looks After Plunging 29%

The Consensus EPS Estimates For OptiNose, Inc. (NASDAQ:OPTN) Just Fell Dramatically

Mar 09
The Consensus EPS Estimates For OptiNose, Inc. (NASDAQ:OPTN) Just Fell Dramatically

OptiNose GAAP EPS of -$0.23 beats by $0.01, revenue of $20.6M misses by $0.9M

Aug 11

OptiNose: Potential Winner In Chronic Sinusitis Treatment

Jun 16

OptiNose: Underappreciated Potential

Mar 10

Earnings and Revenue Growth Forecasts

NasdaqGS:OPTN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026154642253
12/31/2025121-1322-14
12/31/202479-28-6-204
9/30/202476-31-40-40N/A
6/30/202475-41-36-35N/A
3/31/202474-31-32-32N/A
12/31/202371-35-21-21N/A
9/30/202372-41-45-45N/A
6/30/202372-46-58-58N/A
3/31/202373-68-59-59N/A
12/31/202276-75-68-68N/A
9/30/202278-75-67-67N/A
6/30/202280-77-59-59N/A
3/31/202277-82-68-68N/A
12/31/202175-82-77-77N/A
9/30/202168-91-80-79N/A
6/30/202162-95-86-85N/A
3/31/202154-97-87-86N/A
12/31/202049-100-87-86N/A
9/30/202044-101-86-85N/A
6/30/202041-109-85-85N/A
3/31/202037-110-90-89N/A
12/31/201935-110-91-91N/A
9/30/201927-111-94-93N/A
6/30/201916-108-103-102N/A
3/31/201911-105-100-99N/A
12/31/20187-107-94-92N/A
9/30/20184-101-88-85N/A
6/30/20182-93N/A-70N/A
3/31/20181-81N/A-51N/A
12/31/2017N/A-62N/A-36N/A
9/30/2017N/A-43N/A-28N/A
6/30/2017N/A-35N/A-24N/A
3/31/2017N/A-46N/A-24N/A
12/31/2016482N/A22N/A
12/31/20150-40N/A-29N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OPTN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: OPTN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: OPTN is expected to become profitable in the next 3 years.

Revenue vs Market: OPTN's revenue (27.9% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: OPTN's revenue (27.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OPTN's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 05:48
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OptiNose, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gary NachmanBMO Capital Markets Equity Research
John TannerCantor Fitzgerald & Co.
Matthew CaufieldH.C. Wainwright & Co.